HKSE · 1801.HK
Innovent Biologics, Inc.
HK$81.65+HK$0.05 (+0.06%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.55% below the high.
Loading market information…
HKSE · 6998.HK · HKD
Stock price, earnings
Quote as of Oct 29, 2026, 08:08 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Edding Genor Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 59.62% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Edding Genor Group Holdings Limited’s next earnings report is currently expected on Mar 31, 2027, with estimated earnings per share of -HK$0.56. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Edding Genor Group Holdings Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Genor Biopharma Holdings Limited operates as a biopharmaceutical enterprise, concentrating its efforts on the research, development, and commercialization of therapeutic agents for oncology and autoimmune disorders, both within China and globally. Its key investigational medicines include GB242, an infliximab (Remicade) biosimilar. This drug is purposed for the treatment of various conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric Crohn's disease, and fistulizing Crohn's disease. Another prominent candidate is GB491 (lerociclib), an oral CDK4/6 inhibitor currently undergoing Phase III clinical trials for hormone receptor-positive (HR+)/HER2- breast cancer. Additionally, GB492, a stimulator of interferon genes (STING) agonist, is in Phase 1/2 clinical development, with expectations of synergistic effects when combined with GB226 for solid tumor treatment. The company's pipeline also encompasses GB221, a HER2 monoclonal antibody (mAb) designed to mimic trastuzumab (Herceptin); geptanolimab (GB226), a novel PD-1 mAb; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb, which is in Phase I clinical trials; and GB261, also in Phase I clinical trials for B-cell non-Hodgkin Lymphoma. Furthermore, its product candidates in clinical trials for cancer treatment include GB262, GB264, GB265, and GB266. Originally named JHBP (CY) Holdings Limited, the company adopted its current moniker, Genor Biopharma Holdings Limited, in June 2021. Founded in 2007, the firm maintains its headquarters in Shanghai, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:30 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 | Mar 27, 2024 | -HK$0.28+48.26% vs estimate | HK$16.14M+46.73% vs estimate |
|---|
| Q2 2023 | Aug 29, 2023 | -HK$0.58+5.26% vs estimate | HK$0.00-100.0% vs estimate |
|---|
| Q4 2022 | Mar 30, 2023 | -HK$0.72-30.61% vs estimate | HK$14.69M+84.21% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$81.65+HK$0.05 (+0.06%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.55% below the high.
HK$49.68-HK$0.24 (-0.48%)
Shanghai Henlius Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.96% below the high.
HK$11.46-HK$0.21 (-1.8%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 29.26% below the high.
HK$28.02-HK$0.20 (-0.71%)
Ascentage Pharma Group International’s quoted price sits in the lower half of its reported 52-week range, 59.6% below the high.
HK$18.12-HK$0.48 (-2.58%)
Mabwell-b’s quoted price sits in the lower half of its reported 52-week range, 37.9% below the high.
HK$23.60-HK$1.36 (-5.45%)
GenFleet Therapeutics (Shanghai) Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.39% below the high.
HK$5.05+HK$0.31 (+6.55%)
CStone Pharmaceuticals’s quoted price sits in the lower half of its reported 52-week range, 51.54% below the high.
HK$0.43-HK$0.01 (-1.15%)
Mabpharm Limited’s quoted price sits in the lower half of its reported 52-week range, 46.91% below the high.
